Richard-Bildstein, Sylvia published the artcileDiscovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239, Related Products of catalysis-chemistry, the publication is Journal of Medicinal Chemistry (2020), 63(24), 15864-15882, database is CAplus and MEDLINE.
The chemokine receptor CXCR7, also known as ACKR3, is a seven-transmembrane G-protein-coupled receptor (GPCR) involved in various pathologies such as neurol. diseases, autoimmune diseases, and cancers. By binding and scavenging the chemokines CXCL11 and CXCL12, CXCR7 regulates their extracellular levels. From an original high-throughput screening campaign emerged an arylketoamide hit among others. The hit-to-lead optimization led to the discovery of a novel chemotype series of acylaminopiperidinecarboxamides. This series provided CXCR7 antagonists that block CXCL11- and CXCL12-induced ss-arrestin recruitment. Further structural modifications on the acylaminopiperidinecarboxamide framework yielded compounds with high CXCR7 antagonistic activities and balanced ADMET properties. The effort described herein culminated in the discovery of ACT-1004-1239 I. Biol. characterization of I demonstrated that it is a potent, insurmountable antagonist. Oral administration of I in mice up to 100 mg/kg led to a dose-dependent increase of plasma CXCL12 concentration
Journal of Medicinal Chemistry published new progress about 2051-95-8. 2051-95-8 belongs to catalysis-chemistry, auxiliary class Carboxylic acid,Benzene,Ketone, name is 3-Benzoylpropionicacid, and the molecular formula is C10H10O3, Related Products of catalysis-chemistry.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia